search
Back to results

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

Primary Purpose

Overactive Bladder Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Xeomin 100 UNT Injection
Botox 100 UNT Injection
Sponsored by
Walter Reed National Military Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Females 18 years of age or older Primary complaint of urinary urgency incontinence Failed at least one medication (inadequate or poorly tolerated response) or behavior modification technique (timed voiding, pelvic floor physical therapy, dietary modifications, etc.), or decline such interventions Willingness to perform self-catheterization Ability to follow study instructions and complete all required follow-up DEERS eligible Exclusion Criteria: Concurrent use of oral medications for treatment of OAB (anticholinergics or beta 3 agonists) Contraindication to onabotulinumtoxinA and/or incobotulinumtoxin Post void residual volume > 200 ml Symptomatic prolapse POP-Q (Pelvic Organ Prolapse Quantification) stage three or greater that is untreated Evidence of active bladder infection Any previous use of intradetrusor botulinum toxin within the preceding 6 months Total body onabotulinumtoxinA and/or incobotulinumtoxinA dose of ≥ 400 Units in the 3 months prior to scheduled appointment Procedure performed in the main operating room (not outpatient setting) Concurrent diagnosis of interstitial cystitis/painful bladder syndrome Females who are pregnant or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study Neurogenic bladder or other neurological disease that may cause voiding dysfunction Inability to speak or read English. Non-English speakers will be excluded from this study for ease of being able to allow the principal investigator to communicate with the patients during the consents, initial and all follow-up communication. Some of the questionnaires used have also only been validated in English.

Sites / Locations

  • Walter Reed National Military Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Xeomin

Botox

Arm Description

100units xeomin dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each

100units Botox dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each

Outcomes

Primary Outcome Measures

Urge urinary incontinence episodes
To evaluate non-inferiority of incobotulinumtoxinA to onabotulinumtoxinA for treatment of OAB by using number of incontinence episodes on a 24-hours bladder diary at 2-6 weeks post injection

Secondary Outcome Measures

Full Information

First Posted
September 5, 2023
Last Updated
October 11, 2023
Sponsor
Walter Reed National Military Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT06034288
Brief Title
Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
Official Title
IncobotulinumtoxinA (Xeomin®) vs OnabotulimuntoxinA (Botox®) for Treatment of Overactive Bladder Syndrome: Randomized Non-Inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 4, 2023 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Walter Reed National Military Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose: Multiple formulations and brands of botulinum toxin exist on the market today. Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder. IncobotulinumtoxinA (XEOMIN®) is a similar formulation of botulinum toxin A that has similar dosing and safety profile at onabotulinumtoxinA. OnabotulinumtoxinA is the most expensive formulation on the market. Compare the efficacy of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals) to onabotulinumtoxinA (Botox®, Allergan) for treatment of OAB. Study design: A single-blinded, randomized non-inferiority trial of IncobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals) to OnabotulinumtoxinA (Botox®, Allergan) in treatment of OAB. Target Population: The study findings will be applicable to all women 18 years of age or older with OAB symptoms associated with urinary urgency incontinence. Procedure: All patients that presents to urogynecology clinic at Walter Reed National Medical Military Center will be screened for inclusion and exclusion criteria. Patients that meet criteria will be offered to participate in the study. After enrollment patient will complete demographics data sheet, 24 hours bladder diary, OAB-q SF, PGI-S, PISQ-IR. Patients will be randomized by the principal investigator and the allocated treatment will be reveled by the treating provider to the treating provider only. Patient will have a follow up at 2-6 weeks and 6-9 months after procedure. During the follow up appointments patient will be asked to fill out 24-hour voiding diary, OAB-q SF, PGI-I, PGI-S, and PISQ-IR surveys.
Detailed Description
The study will be registered on clinicaltrials.gov after IRB approval. Institutional Review Board (IRB) approval will be received. All women 18 years of age and older with bothersome overactive bladder symptoms who are receiving care at Walter Reed National Military Medical Center (WRNMMC) in the urogynecology clinic will be eligible for the study. All study participants will undergo a complete intake assessment to include a history, physical exam, post-void bladder residual volume assessment via straight catheterization or ultrasound, and counseling on treatment modalities for OAB using the AUGS handout to include behavioral and dietary modifications, physical therapy, oral medications, onabotulinumtoxinA and neuromodulation. Patients desiring treatment with onabotulinumtoxinA will be scheduled for the procedure. Patients do not have to fail prior treatment options in order to qualify for bladder BOTOX. This is all standard of care in our practice. All patients meeting the inclusion and exclusion criteria will be offered enrollment in this study. Enrollment will be done by the research team, who typically are also the clinicians. No patients will be pressured or coerced into participating in the study. Prior to the procedure appointment, participants will be consented for participation in the study and asked to complete demographics data sheet, 24 hours bladder diary, OAB-q SF, PGI-S, PISQ-IR. OAB-q SF is a standard of are in our practice, all other questionnaires patient will fill out for the purpose of this study. The procedure will be performed at Walter Reed National Military Medical Center either in clinic setting or in the operating room. All patients who plan to undergo the procedure in clinic will be offered a pre-treatment anxiolytic with a single dose of 5-10mg of oral diazepam, which is standard practice at this institution. Patients undergoing the procedure in the operating room, will be given sedation medications as per standard of care. As standard of treatment, patients will also be given a prescription for an antibiotic - either nitrofurantoin 100mg to take orally twice daily for 3 days starting the day of the procedure, or trimethoprim-sulfamethoxazole 800mg-160mg to take orally twice daily for 3 days starting the day of the procedure depending on patient's allergy profile. The principal investigator will make randomized assignments using the RAND function in excel. The first 32 random numbers will be assigned to BOTOX arm and the second 32 numbers will be assigned to XEOMIN arm. Each assignment number will be placed in a sealed envelop by the PI. The sealed envelops will be opened by the treatment provider the day of the scheduled procedure. The envelop will reveal the medication assignment to the provider. After the provider reveals the medication only to him/herself (not the patient), the appropriate medication will be obtained from the pharmacy and administered to the patient. The patient will be blinded to the treatment allocation. The drug will be obtained from the pharmacy on the day of the procedure by the treatment team. Either onabotulinumtoxinA or incobotulinumtoxinA (as determined by the allocated assignment), will be reconstituted in 10 milliliters of injectable saline by the treatment team prior to entering the patient's room, to keep the patient blinded. The bladder will be filled with 20ml of 2% viscous lidocaine through the urethra 15 to 20 minutes prior to the procedure per the Urogynecology department standard operating procedure for intradetrusor onabotulinumtoxinA injections. Operative cystoscopy will be performed, and an adjustable-depth injection cystoscopy needle will be used to inject the blinded study drug (either 100 units of onabotulinumtoxinA (Botox®, Allergan) or 100 units of incobotulinumtoxinA (Xeomin®, Merz Pharmaceutical)) with the needle depth set to 3mm. Injections will be performed by either a board-certified staff Urogynecologist, or fellows or residents working under their direct supervision of the board-certified staff urogynecologist. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted study medication at each injection site, approximately 1cm apart along the posterior bladder wall making sure to avoid the trigone, for a total or 20 injection sites (4 rows of 5 injection sites). After the completion of the procedure, patients will be asked to start taking their prescribed antibiotics and to continue them for 3 days. If a known UTI was inadequately treated prior to procedure appointment, or if there is evidence of an active infection at the time of cystoscopy, the intravesical injection will not be completed and patient will be rescheduled. Participants will have a follow-up appointment in 2-6 weeks following the procedure in person, via phone or email. At the follow-up visit patients will be asked to complete a 24-hour bladder diary, OAB-q SF, PGI-I, PGI-S, PISQ-IR surveys. The surveys will either be read or emailed to the patient based on patient's preference. Patients will be asked regarding urinary tract infection (UTI) symptoms and whether they needed clean intermittent catheterization (CIC). The electronic health record (EHR) will also be reviewed to confirm whether UTI has occurred or if CIC needed to be done. Patients will be asked whether they are experiencing painful urination, urinary frequency, urinary urgency, or blood in their urine. If patients answer yes to any of those questions, they will be asked to provide a urine sample. If this follow up is being done in person, then a urine sample will be obtained via straight catheterization during the appointment. If the follow up visit is being done virtually, patient will be asked to come into clinic or laboratory and provide a urine sample via straight catheterization or clean catch for urinalysis and urine culture to assess for UTI. If infection is present, patients will receive appropriate antibiotics based on culture sensitivities. Patients found to have an active infection at the time of postprocedural follow-up will be asked to complete the study questionnaires 2-4 weeks following treatment of infection. Patients will also be asked if they experienced any other symptoms following the procedure that concerned them and any symptoms reported will be recorded. Participants who experience initial relief in their symptoms following injection of the study medication but then experience recurrence of symptoms will be eligible for repeat injection provided it has been at least 12 weeks from prior injection and the total dose of onabotulinumtoxinA/incobotulinumtoxinA does not exceed 400 units in a three-month time frame, as is standard of care. Six to nine months following the treatment, patients will be contacted via phone or email and asked to complete a 24-hour voiding diary, OAB-q SF, PGI-I, PGI-S, and PISQ-IR surveys for final assessment of symptoms following treatment. They will again be asked regarding adverse events. The questionnaires again will either be read to the patient via phone or emailed based on patient's preference. This research study is a single-blind study. Unblinding of subjects will be performed at the conclusion of the study after enrollment is closed and data collection is complete. Participants will not be notified of their group assignment unless it is requested after the completion of the final follow up encounter. If the participant would like to know their group assignment, they will contact the PI who will release that information to them after the conclusion of the study. Study participants who request to be un-blinded as to their randomized assigned group early will need to be withdrawn from the study. The participant will supply a request in writing to the PI. Any data regarding that participant will be removed from the records and that assignment number will be noted as withdrawn. A memorandum for record will be created outlining the subject's request and both the MFR and subject's written request will be maintained with the data collection for reference. In the event of an emergency, there is a way to find out which one the participant is receiving. If there is a medical emergency that may require unblinding prior to the conclusion of the study, the research team will work in coordination with the subject's primary care or emergency provider to determine if unblinding is necessary and make that information available to them as needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Xeomin
Arm Type
Experimental
Arm Description
100units xeomin dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
Arm Title
Botox
Arm Type
Active Comparator
Arm Description
100units Botox dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
Intervention Type
Drug
Intervention Name(s)
Xeomin 100 UNT Injection
Other Intervention Name(s)
incobotulinumtoxinA
Intervention Description
intravesical injection
Intervention Type
Drug
Intervention Name(s)
Botox 100 UNT Injection
Other Intervention Name(s)
onabotulinumtoxinA
Intervention Description
intravesical injection
Primary Outcome Measure Information:
Title
Urge urinary incontinence episodes
Description
To evaluate non-inferiority of incobotulinumtoxinA to onabotulinumtoxinA for treatment of OAB by using number of incontinence episodes on a 24-hours bladder diary at 2-6 weeks post injection
Time Frame
2-6 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Females 18 years of age or older Primary complaint of urinary urgency incontinence Failed at least one medication (inadequate or poorly tolerated response) or behavior modification technique (timed voiding, pelvic floor physical therapy, dietary modifications, etc.), or decline such interventions Willingness to perform self-catheterization Ability to follow study instructions and complete all required follow-up DEERS eligible Exclusion Criteria: Concurrent use of oral medications for treatment of OAB (anticholinergics or beta 3 agonists) Contraindication to onabotulinumtoxinA and/or incobotulinumtoxin Post void residual volume > 200 ml Symptomatic prolapse POP-Q (Pelvic Organ Prolapse Quantification) stage three or greater that is untreated Evidence of active bladder infection Any previous use of intradetrusor botulinum toxin within the preceding 6 months Total body onabotulinumtoxinA and/or incobotulinumtoxinA dose of ≥ 400 Units in the 3 months prior to scheduled appointment Procedure performed in the main operating room (not outpatient setting) Concurrent diagnosis of interstitial cystitis/painful bladder syndrome Females who are pregnant or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study Neurogenic bladder or other neurological disease that may cause voiding dysfunction Inability to speak or read English. Non-English speakers will be excluded from this study for ease of being able to allow the principal investigator to communicate with the patients during the consents, initial and all follow-up communication. Some of the questionnaires used have also only been validated in English.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna S Trikhacheva, MD
Phone
7162353843
Email
ann_trik@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna S Trikhacheva, MD
Organizational Affiliation
Walter Reed Army Institute of Research (WRAIR)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
anna trikhacheva, md
Phone
716-235-3843
First Name & Middle Initial & Last Name & Degree
christine vaccaro, md
Phone
3014002469

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

We'll reach out to this number within 24 hrs